Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.The Motley Fool • 02/12/26
Novo Nordisk faces a defining year in the obesity drug market. It's off to a dramatic startCNBC • 02/11/26
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugsCNBC • 02/11/26
Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?Zacks Investment Research • 02/11/26
Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded SemaglutideZacks Investment Research • 02/10/26
Novo Nordisk's latest salvo against Hims & Hers—a patent-infringement lawsuit—shows the fierce maneuvering over the booming obesity-drug marketWSJ • 02/09/26
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New TurnInvestopedia • 02/09/26
Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injectionsCNBC • 02/09/26